Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALETA-001 in B-cell Malignancies Post CD19 CAR T-cell Therapy
NCT06045910Phase 2Recruiting
- Sponsor
- Cancer Research UK
- Start
- Feb 2024
- Primary completion
- Feb 2028
- Modality
- Recombinant Proteins and Enzymes, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 2 trial of ALETA-001 in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), B cell lymphoma, sponsored by Cancer Research UK. Started Feb 2024; status: recruiting.
02
Drugs
ALETA-001
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)follicular lymphoma (FL)B cell lymphoma
Beyond the preview
Go deeper on NCT06045910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06045910.